AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung ...

April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...

(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.

Multinational giant AbbVie’s empire has mostly been built on its famed arthritis drug Humira, since its approval in the U.S. in 2002. But now, with a fall in revenues owing to expiring patents, AbbVie ...

This week’s news that AbbVie CEO Richard Gonzalez will retire in July after 11 years at the helm is essentially him declaring victory. Despite the U.S. patent cliff for its blockbuster ...

The drop in Humira revenue “is tracking as expected, with much of the impact driven by price,” said AbbVie Chairman and CEO Richard Gonzalez, in an earnings call Thursday morning. Humira is ...

A lawsuit has been filed against pharmaceutical giant AbbVie over the high price tag on its best-selling drug Humira and a practice it allegedly engages in to help pharmacy benefit managers pocket ...

Earnings per share (EPS) at AbbVie are expected to fall to $1.50 from $2.51 a year ago. In January, the company lost patent protection on its top-selling drug, Humira, which has been protected ...